ACE Report Cover
Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Langue
Download Download Download
Télécharger
Cite this Report Cite this Report Cite this Report
Citer
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoris
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Langue
Download Download Download
Télécharger
Cite this Report Cite this Report Cite this Report
Citer
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoris
SPINE
Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2014;2(3):23 PLoS One. 2013 Nov 22;8(11):e82063
Auteurs contributeurs

C Yuan H Zhang S He

9 randomized controlled studies, with a total of 664 patients, were included in this meta-analysis to compare antifibrinolytic agents such as tranexamic acid (TXA) and epsilonaminocaproic acid (EACA), to a placebo in regards to blood loss, transfusion requirements and deep vein thrombosis incidence in patients who underwent spine surgery. The antifibrinolytic agents were effective in reducing total blood loss, total blood transfusion and ratio of blood transfusion; additionally, the incidence of deep vein thrombosis was comparable between the antifibrinolytic agents and the placebos used.


Détails du financement de la publication +
Financement:
Non-funded
Conflicts:
None disclosed

Risque de partialité

10/10

Critères de déclaration

19/20

Indice de fragilité

N/A

Were the search methods used to find evidence (original research) on the primary question or questions stated?

Was the search for evidence reasonably comprehensive?

Were the criteria used for deciding which studies to include in the overview reported?

Was the bias in the selection of studies avoided?

Were the criteria used for assessing the validity of the included studies reported?

Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?

Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?

Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?

Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?

How would you rate the scientific quality of this evidence?

Oui = 1

Incertain = 0,5

Non pertinent = 0

Non = 0

L'évaluation des critères de rapport permet d'évaluer la transparence avec laquelle les auteurs rapportent les caractéristiques méthodologiques et les caractéristiques de l'essai dans la publication. L'évaluation est divisée en cinq catégories qui sont présentées ci-dessous.

4/4

Introduction

4/4

Accessing Data

4/4

Analysing Data

4/4

Results

3/4

Discussion

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'indice de fragilité est un outil qui aide à l'interprétation des résultats significatifs, en fournissant une mesure de la force d'un résultat. L'indice de fragilité représente le nombre d'événements consécutifs qui doivent être ajoutés à un résultat dichotomique pour que le résultat ne soit plus significatif. Un petit nombre représente un résultat plus faible et un grand nombre un résultat plus fort.

Pourquoi cette étude était-elle nécessaire maintenant ?

Spine surgery, particularly multilevel spinal fusion, deformity correction and anterior-posterior spinal fusion, are associated with significant blood loss and transfusion requirements. Transfusions can be the cause of a variety of complications which can be decreased with autologous blood donations, application of cell saver-systems or the use of erythropoietin; however, these solutions are expensive and logistically challenging. Intraoperative administration of antifibrinolytics such as tranexamic acid (TXA), epsilonaminocaproic acid (EACA) and aprotinin are becoming more popular in spine surgery. Recent high-quality evidence provides reason to conduct a current meta-analysis on the topic; therefore, this study was conducted to determine the effects of antifibrinolytic agents on reducing perioperative blood loss in spine surgery.

Quelle était la principale question de recherche ?

What are the effects of antifibrinolytic agents such as tranexamic acid (TXA) and epsilonaminocaproic acic (EACA) on perioperative blood loss and transfusion requirements in patients undergoing spine surgery?

Caractéristiques de l'étude +
Data Source:
The search was performed using MEDLINE, EMBASE and the Cochrane Library databases for all studies written in English published by October 2012. WHO International Clinical Trials Registry Platform, UK National Research Register Archive and Current Controlled Trials from their inception to October 2012 for unpublished trials. All reference lists were searched for relevant articles.
Index Terms:
Spine surgery, spinal surgery, antifibrinolytic agents, tranexamic acid, and epsilonaminocaproic acid
Study Selection:
9 randomized controlled trials that compared TXA or EACA to a placebo in spine surgery and reported on at least one of blood loss, blood transfusion, ratio of blood transfusion, or incidence of deep vein thrombosis (DVT) were independently selected by two reviewers; discrepancies were resolved through discussion.
Data Extraction:
Data extraction of authors, year of publication, country, sample size, age, gender, drug dosage, transfusion indication, duration of surgery, total blood loss, blood transfusion, ratio of blood transfusion, and incidence of DVT.
Data Synthesis:
Data analyses were performed with Review Manager Version 5.2. Continuous outcomes were pooled as weight mean difference (WMD) with 95% confidence intervals (CI) and risk ratios (RR) with 95% CIs were used to evaluate dichotomous data. Significant outcomes had a p value of less than 0.05. A fixed-effects model was used for data that was not significantly heterogeneous (p>0.05) and a random-effects model was used significantly heterogeneous data (p<0.05).
Quels sont les résultats importants ?
  • 8 studies reported on total blood loss, the overall effect was significantly different in favour of the intervention (WMD =-288.8, 95 % CI -46.49 to -110.19; p = 0.002).Subgroup analyses of 6 studies that examined TXA and 2 studies evaluating EACA resulted in similar conclusions (WMD =-285.3, 95 % CI -506.99 to -63.65; p = 0.01 and WMD =-338.1, 95 % CI -583.03 to -93.33; p = 0.007, respectively).
  • The 9 studies that reported on total blood transfusion and found a significant difference in favour of antifibrinolytic agents(WMD =-242.76, 95 % CI -422.5 to -62.95; p = 0.008). Subgroup analysis of 6 studies involving TXA indicated significant differences in favour of TXA (WMD=-242.76, 95 % CI -422.5 to -62.95; p = 0.008) and 3 studies display improved results with EACA as well compared to a placebo (WMD =-358.1, 95 % CI -608.49 to -107.71; p = 0.005)
  • Ratio of blood transfusion was available in 7 studies and overall antifibrinolytic agents proved superior over the placebo (RR = 0.73, 95% CI 0.58 to 0.93; p = 0.010). A subgroup analysis of TXA alone resulted in similar findings (RR =0.71, 95 % CI 0.54 to 0.92; p= 0.01).
  • 9 Studies examined the DVT incidence and found no difference between groups (RR 0.25, 95 % CI 0.03 to 2.22; p= 0.21).
De quoi dois-je me souvenir en priorité ?

The antifibrinolytic agents tranexamic acid (TXA) and epsilonaminocaproic acid (EACA) were both effective in reducing total blood loss, total blood transfusion and ratio of blood transfusion. The incidence of deep vein thrombosis was comparable between the antifibrinolytic agents and the placebos used.

Comment cela affectera-t-il les soins prodigués à mes patients ?

Results of this study suggest that patients undergoing spine surgery can benefit from the administration of antifibrinolytic agents such as tranexamic acid and epsilonaminocaproic acid in terms of reducing blood loss and transfusion requirements. This study was limited by the small sample sizes of the included trials and the heterogeneity in variation in drug dose, surgical procedure, operation time, age of patients, protocol for estimating blood loss and transfusion indication. All of the included studies featured intravenous administration of the study drugs; whether there is a role of topical agents in spine surgery remains to be determined.

AVIS DE NON-RESPONSABILITÉ

Le contenu de cette page est fourni à titre d'information uniquement et n'est pas destiné à remplacer un avis médical, un diagnostic ou un traitement professionnel. Si vous avez besoin d'un traitement médical, demandez toujours l'avis de votre médecin ou rendez-vous au service des urgences le plus proche. Les opinions, croyances et points de vue exprimés par les individus sur le contenu de cette page ne reflètent pas les opinions, croyances et points de vue d'OrthoEvidence.

0 de 4 articles mensuels GRATUITS débloqués
Vous avez atteint votre limite de 4 vues d'articles gratuits ce mois-ci

Accédez à OrthoEvidence pour seulement 1,99 $ par semaine.

Restez informé des dernières données. Annulez à tout moment.
  • Évaluations critiques des derniers essais contrôlés randomisés à fort impact et des revues systématiques en orthopédie.
  • Accès au contenu des podcasts OrthoEvidence, y compris les collaborations avec le Journal of Bone and Joint Surgery, les entretiens avec des chirurgiens de renommée internationale et les tables rondes sur l'actualité et les sujets orthopédiques.
  • Abonnement à The Pulse, une lettre d'information bihebdomadaire fondée sur des données probantes, conçue pour vous aider à prendre de meilleures décisions cliniques.
Upgrade
Bienvenue à nouveau !
Vous avez oublié votre mot de passe ?
Commencez votre essai GRATUIT dès aujourd'hui !

Votre compte sera affilié à
et inclut un accès gratuit à OrthoEvidence.


OU
Vous avez oublié votre mot de passe ?

OU
Veuillez vérifier votre adresse électronique

Si un compte existe avec l'adresse e-mail fournie, un e-mail de réinitialisation du mot de passe vous sera envoyé. Si vous ne voyez pas d'e-mail, veuillez vérifier votre dossier de spam ou de courrier indésirable.

Pour plus d'assistance, contactez notre équipe d'assistance.

Veuillez vous connecter pour activer cette fonction

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte OrthoEvidence actif. Veuillez vous connecter ou créer un compte d'essai GRATUIT.

Traduire le rapport ACE

OrthoEvidence utilise un service de traduction tiers pour rendre le contenu accessible dans plusieurs langues. Veuillez noter que même si tous les efforts sont faits pour assurer l'exactitude, les traductions ne sont pas toujours parfaites.

Comment citer ce document ACE Report

OrthoEvidence. Antifibrinolytic agents reduce blood loss and transfusion requirements in spine surgery. OE Journal. 2014;2(3):23. Available from: https://myorthoevidence.com/AceReport/Show/antifibrinolytic-agents-reduce-blood-loss-and-transfusion-requirements-in-spine-surgery

Copier la citation
Veuillez vous connecter pour activer cette fonction

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte OrthoEvidence actif. Veuillez vous connecter ou créer un compte d'essai GRATUIT.

Fonctionnalité Membre Premium

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte Premium OrthoEvidence.

Partager ACE Report